Liminatus gains amid review to consider digital assets for treasury management

[Glowing dollar symbol, cryptocurrency network, neon green dollar symbol, blue blockchain links, futuristic finance tech, global economy, cyberpunk aesthetic. 3D render.]

* Liminatus Pharma (NASDAQ:LIMN [https://seekingalpha.com/symbol/LIMN]) added 9% on Tuesday after the company launched a review to consider if it could leverage digital assets in a broader treasury management framework.
* As part of the review, the preclinical-stage cancer drug developer will assess whether novel financial instruments, including blockchain-based assets, could help improve its treasury efficiency and diversify non-operating capital reserves.
* However, the La Palma, California-based biotech emphasized that the review remains exploratory, and it has not reached an agreement regarding the acquisition, use, and custody of digital assets.
* “Liminatus remains fully committed to our mission of developing life-changing cancer therapies,” CEO Chris Kim remarked. “This review is not a shift in our business focus but an effort to evaluate modern financial tools—such as regulated digital assets—that may enhance the way we manage non-operating capital.” [https://seekingalpha.com/pr/20174106-liminatus-pharma-inc-initiates-strategic-review-of-blockchain-integrated-treasury-strategy]

MORE ON LIMINATUS PHARMA, INC.

* Liminatus Pharma: CD47 Hasn't Worked For Anyone, But Is This The Exception? [https://seekingalpha.com/article/4796849-liminatus-pharma-cd47-hasnt-worked-for-anyone-but-is-this-the-exception]
* Financial information for Liminatus Pharma, Inc. [https://seekingalpha.com/symbol/LIMN/income-statement]